GenSight Biologics S.A.
SIGHT.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €26 | €22 | €156 | €251 |
| - Cash | €2 | €2 | €11 | €44 |
| + Debt | €19 | €24 | €13 | €13 |
| Enterprise Value | €43 | €44 | €158 | €219 |
| Revenue | €3 | €1 | €3 | €5 |
| % Growth | 107.2% | -50.9% | -51.1% | – |
| Gross Profit | €3 | €3 | €3 | €5 |
| % Margin | 100% | 236.8% | 100% | 100% |
| EBITDA | -€15 | -€22 | -€27 | -€26 |
| % Margin | -562.1% | -1,715.1% | -1,036.9% | -483.7% |
| Net Income | -€14 | -€26 | -€28 | -€29 |
| % Margin | -533.4% | -2,069.5% | -1,069.9% | -542.4% |
| EPS Diluted | -0.15 | -0.54 | -0.6 | -0.63 |
| % Growth | 72.2% | 10% | 4.8% | – |
| Operating Cash Flow | -€13 | -€25 | -€34 | -€17 |
| Capital Expenditures | -€0 | -€0 | -€0 | -€0 |
| Free Cash Flow | -€13 | -€25 | -€34 | -€17 |